Table 1

 Baseline characteristics of patients who were eligible for dose escalation

Assessment*No dose escalation (n = 220)Received dose escalation (n = 109)†Primary non-responders‡ (n = 53)§Secondary non-responders¶ (n = 47)§Dose escalated to 9 mg/kg (n = 7)
CRP, C reactive protein; HAQ, Health Assessment Questionnaire
*All values are medians (interquartile range) unless otherwise specified.
†All patients who received at least one dose escalation are included.
‡A primary non-responder was a patient who did not respond at week 22.
§Patients who received dose escalations incorrectly are not included.
¶A secondary non-responder was a patient who responded at week 22 but later flared.
Women, No (%)170 (77.3)92 (84.4)46 (86.8)40 (85.1)6 (85.7)
Age (years)54.0 (44.0, 62.0)53.0 (47.0, 59.0)52.0 (47.0, 64.0)54.0 (45.0, 59.0)57.0 (44.0, 66.0)
Weight (kg)69.3 (60.1, 81.0)72.0 (61.4, 83.0)69.0 (61.0, 78.0)75.0 (63.0, 86.0)74.5 (59.3, 77.7)
Disease duration (years)8.2 (3.5, 14.5)8.2 (3.1, 16.5)9.4 (5.2, 17.9)7.3 (2.5, 14.3)12.1 (1.8, 23.9)
Swollen joint count16.0 (11.0, 22.0)13.0 (9.0, 17.0)14.0 (9.0, 22.0)13.0 (9.0, 16.0)12.0 (9.0, 17.0)
Tender joint count23.0 (16.5, 31.0)21.0 (14.0, 28.0)25.0 (16.0, 33.0)19.0 (13.0, 25.0)23.0 (11.0, 31.0)
HAQ (0–3)1.5 (1.0, 1.9)1.6 (1.0, 2.0)1.9 (1.1, 2.1)1.5 (1.0, 1.9)1.1 (0.9, 2.4)
Corticosteroids at baseline, No (%)133 (60.5)65 (59.6)29 (54.7)32 (68.1)4 (57.1)
Extra-articular manifestations (%)89 (40.5)38 (34.9)20 (37.7)15 (31.9)3 (42.9)
CRP (mg/l)17 (7, 32)16 (7, 33)14 (7, 28)16 (7, 30)7 (4, 12)
Methotrexate (mg/week)15.0 (10.0, 17.5)15.0 (10.0, 15.0)15.0 (10.0, 15.0)15.0 (10.0, 17.5)15.0 (10.0, 25.0)